Vertex Pharmaceuticals Hits 52-Week High Amid Regulatory and Developmental Catalysts
Vertex Pharmaceuticals (VRTX) has surged over 10% in recent weeks to reach a new 52-week high, driven by regulatory approvals for its gene-editing therapy Casgevy and pending approval of povetacicept. These developments are expected to expand the company's market potential significantly.
Tickers: $VRTX
Topics: Casgevy gene therapy IgA nephropathy povetacicept Vertex Pharmaceuticals